Pfizer (PFE) Tops Q3 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
PFIZER REPORTS THIRD-QUARTER 2015 RESULTS
October 27, 2015 6:45 AM EDTThird-Quarter 2015 Reported Revenues(1) of $12.1 Billion Increased 6% Operationally, Which Includes $0.3 Billion Reflecting One Month of Legacy Hospira U.S. Operations Third-Quarter 2015 Adjusted Diluted EPS(2) of $0.60 and Reported Diluted EPS(1) of $0.34, Which Includes One Month of Legacy Hospira U.S. Operations Third-Quarter 2015 Reported Revenues(1) for Pfizer-Standalone (Excluding Legacy Hospira) Increased 4% Operationally; Innovative Products Business Grew 21% Operationally, Primarily Driven by Prevnar 13 Adult and Ibrance Raised Midpoint of 2015 Financial Guidance Ranges for Reported Revenues(1) by $1.0 Billion and Adjusted Diluted EPS(2) by $0.11, Primarily Reflecting Strong Performance to Date and Improved... More
